INNOVEN: InnovaMatrix® AC for Venous Leg Ulcers
This study, called INNOVEN, is looking at how well a product called InnovaMatrix® AC works for hard-to-heal venous leg ulcers (open sores on the leg caused by poor blood flow). You would receive either InnovaMatrix® AC plus the usual care, or just the usual care alone. Researchers want to see if adding InnovaMatrix® AC helps these ulcers close completely within 12 weeks. To join, you must be at least 21 years old and have a leg ulcer between 1 and 25 square centimeters that has been present for at least 4 weeks. The current status of this study is unclear, so it's not known if they are actively looking for participants.
- Study design
- This is a randomized controlled trial, meaning participants are assigned by chance to one of two groups. It aims to enroll 120 people and is observer-blinded, so some study staff won't know which treatment you are receiving.
- What's involved
- You would receive weekly dressing applications of InnovaMatrix® AC if you are in that group. The primary goal is measured at 12 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- The main outcome is measured at 12 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
INNOVEN: Efficacy of Porcine Placental Extracellular Matrix Plus Standard of Care (SOC) Versus SOC Alone
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Thomas E. Serena, MD FACS · PRINCIPAL_INVESTIGATOR · SerenaGroup, Inc.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Determine the efficacy of Porcine Placental Extracellular Matrix (PPECM) plus Standard of Care (SOC) versus SOC alone in achieving complete closure of hard-to-heal venous leg ulcers over 12 weeks.12 weeks
The percentage of target ulcers achieving complete wound closure defined as complete epithelialisation of the wound surface.